Anti-IL-1β (Canakinumab), Human IgG1 Antibody

Anti-IL-1β (Canakinumab), Human IgG1 Antibodyis available at Gentaur for Next week Delivery.

Description: The research-grade biosimilar is a recombinant human IgG1 kappa monoclonal antibody that is produced in murine Sp2/0-Ag14 cell line. This antibody binds to and neutralizes human IL-1β preventing association with its receptor and subsequent inflammatory signaling cascade. The antibody neither has cross-reactivity with IL-1α nor with the Interleukin 1 receptor, type I (IL1R1). The original monoclonal antibody was developed to treat rheumatoid arthritis. It received FDA approval in 2009 to treat cryopyrin-associated periodic syndromes (CAPS). Additionally, in 2016, the original antibody also received approval for the treatment of Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS), Hyperimmunoglobulinemia D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD), and Familial Mediterranean Fever (FMF).

Immunogen Sequence:Canakinumab

Target Alternative Name:IL-1, IL1F2, IL1beta, IL1-BETA, IL1B

Species Reactivities:Human

Tag Line:A human monoclonal antibody that targets and neutralizes IL-1β and prevents IL-1 mediated autoinflammatory disorders

Formulation:In PBS pH 7.5

Purification: Protein A purified

Application:/

Positive Control:/

Application And Usages:/

Handling:The antibody solution should be gently mixed before use.